Search CTMX
CytomX Therapeutics, Inc.
NasdaqGS · CIK 1501989
Last close2.56
Daily change-0.07 (-2.66%)
10 Years gain-83.51%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CTMX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
57.3Momentum
0.0Acceleration
0.0Confidence
76.0Annual Revenue13
Quarterly Revenue52
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.5 / 25
Quality14.8 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 186.5351 percentage points.
Heavy share dilution · HIGHDiluted share count increased 151.2194%.
Key Metrics
Revenue Growth TTM-75.95%OK
Revenue CAGR 3Y12.75%OK
Gross Margin100%OK
Operating Margin-166.7%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y151.22%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $76.20M | $76.20M | -$22.36M | -$75.59M | -$75.81M | 100% | -29.35% | -99.48% | n/a | 137.94M |
| 2025 FY Dec 31, 2024 | $138.10M | $138.10M | $25.00M | -$86.23M | -$86.54M | 100% | 18.1% | -62.66% | n/a | 84.75M |
| 2024 FY Dec 31, 2023 | $101.21M | $101.21M | -$6.48M | -$56.04M | -$56.88M | 100% | -6.41% | -56.19% | n/a | 73.81M |
| 2023 FY Dec 31, 2022 | $53.16M | $53.16M | -$101.34M | -$110.79M | -$112.53M | 100% | -190.61% | -211.67% | n/a | 65.74M |
| 2022 FY Dec 31, 2021 | $37.31M | $37.31M | -$116.04M | -$119.03M | -$120.64M | 100% | -311% | -323.33% | n/a | 64.15M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $36.30M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-337950, 0001193125-25-269477 |
| Revenue Growth TTM | -75.95% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-337950, 0001193125-25-269477 |
| Revenue CAGR 3Y | 12.75% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-107146 |
| Revenue CAGR 5Y | 2.18% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-107146 |
| Gross Profit CAGR 3Y | 12.75% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-107146 |
| Operating Income Growth | -302.11% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-337950, 0001193125-25-269477 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-337950, 0001193125-25-269477 |
| Operating Margin | -166.7% | Operating Income / Revenue | OK | 0001193125-26-337950, 0001193125-25-269477 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-337950 |
| Current Ratio | 9.36x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.17 | Revenue / Diluted Shares | OK | 0001193125-26-337950, 0001193125-25-269477 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-107146 |